Gemma Bruera

561 total citations
47 papers, 451 citations indexed

About

Gemma Bruera is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Gemma Bruera has authored 47 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 12 papers in Hepatology. Recurrent topics in Gemma Bruera's work include Colorectal Cancer Treatments and Studies (34 papers), Cancer Treatment and Pharmacology (14 papers) and Hepatocellular Carcinoma Treatment and Prognosis (12 papers). Gemma Bruera is often cited by papers focused on Colorectal Cancer Treatments and Studies (34 papers), Cancer Treatment and Pharmacology (14 papers) and Hepatocellular Carcinoma Treatment and Prognosis (12 papers). Gemma Bruera collaborates with scholars based in Italy, France and Greece. Gemma Bruera's co-authors include Enrico Ricevuto, Corrado Ficorella, Katia Cannita, Paolo Marchetti, Aldo Victor Giordano, Adelmo Antonucci, Edoardo Alesse, Antonio Russo, Stefano Guadagni and Giancarlo Troncone and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Gemma Bruera

45 papers receiving 447 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gemma Bruera Italy	13	329	129	85	79	78	47	451
Nuria Rodrı́guez-Salas Spain	13	307 0.9×	99 0.8×	114 1.3×	41 0.5×	140 1.8×	32	485
Boyang Chang China	12	224 0.7×	94 0.7×	76 0.9×	70 0.9×	142 1.8×	26	458
Mutsumi Fukunaga Japan	12	343 1.0×	188 1.5×	50 0.6×	58 0.7×	84 1.1×	77	535
Kyung Kee Baek South Korea	9	219 0.7×	107 0.8×	94 1.1×	33 0.4×	90 1.2×	13	401
Aurélie Ferru France	11	250 0.8×	82 0.6×	86 1.0×	17 0.2×	93 1.2×	30	439
Francesca Comito Italy	10	131 0.4×	113 0.9×	79 0.9×	96 1.2×	77 1.0×	26	331
Shonan Sho United States	11	254 0.8×	72 0.6×	166 2.0×	37 0.5×	93 1.2×	16	443
Ashish Manne United States	10	300 0.9×	100 0.8×	41 0.5×	34 0.4×	57 0.7×	44	430
Nikoletta Sidiropoulos United States	8	163 0.5×	114 0.9×	135 1.6×	51 0.6×	76 1.0×	21	336
Sabina Murgioni Italy	11	214 0.7×	145 1.1×	76 0.9×	23 0.3×	73 0.9×	38	361

Countries citing papers authored by Gemma Bruera

Since Specialization

Citations

This map shows the geographic impact of Gemma Bruera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gemma Bruera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gemma Bruera more than expected).

Fields of papers citing papers by Gemma Bruera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gemma Bruera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gemma Bruera. The network helps show where Gemma Bruera may publish in the future.

Co-authorship network of co-authors of Gemma Bruera

This figure shows the co-authorship network connecting the top 25 collaborators of Gemma Bruera. A scholar is included among the top collaborators of Gemma Bruera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gemma Bruera. Gemma Bruera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guadagni, Stefano, Francesco Masedu, Giammaria Fiorentini, et al.. (2022). Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases. BMC Cancer. 22(1). 660–660. 1 indexed citations

Guadagni, Stefano, Antonietta R. Farina, Lucia Cappabianca, et al.. (2020). Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A. International Journal of Molecular Sciences. 21(21). 8222–8222. 5 indexed citations

Guadagni, Stefano, Marco Clementi, Andrew R. Mackay, et al.. (2020). Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study. Journal of Cancer Research and Clinical Oncology. 146(5). 1273–1290. 16 indexed citations

Bruera, Gemma, Antonio D’Andrilli, Maurizio Simmaco, et al.. (2020). Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy. Frontiers in Oncology. 10. 1155–1155. 2 indexed citations

Bruera, Gemma & Enrico Ricevuto. (2020). <p>Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments</p>. Pharmacogenomics and Personalized Medicine. Volume 13. 601–617. 8 indexed citations

Guadagni, Stefano, Giammaria Fiorentini, Michele De Simone, et al.. (2019). Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study. Journal of Cancer Research and Clinical Oncology. 146(1). 205–219. 16 indexed citations

Bruera, Gemma, Antonio Giuliani, Lucia Romano, et al.. (2019). Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice. BMC Cancer. 19(1). 960–960. 4 indexed citations

Tessitore, Alessandra, Gemma Bruera, Katia Cannita, et al.. (2018). KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. Human Pathology. 74. 178–182. 3 indexed citations

Bruera, Gemma, Francesco Pepe, Umberto Malapelle, et al.. (2017). Differential clinical outcome according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing of metastatic colorectal cancer patients treated with first line FIr-B/FOx adding bevacizumab to triplet chemotherapy. Annals of Oncology. 28. iii95–iii96.

10.

Bruera, Gemma, Francesco Pepe, Umberto Malapelle, et al.. (2017). Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. Annals of Oncology. 28. vi14–vi14. 1 indexed citations

11.

Ricevuto, Enrico, et al.. (2017). Effects of Chemotherapy in Patients with Concomitant Aortic Aneurysm and Malignant Disease. Annals of Vascular Surgery. 45. 268.e13–268.e20. 10 indexed citations

12.

Bruera, Gemma, Alessia Catalucci, Pierluigi Bonfili, et al.. (2015). Temozolomide dose-dense regimen in high grade gliomas: dose-finding/phase II study. Annals of Oncology. 26. vi138–vi138. 1 indexed citations

13.

Bruera, Gemma, Katia Cannita, Eleonora Palluzzi, et al.. (2014). Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer. BioMed Research International. 2014. 1–7. 10 indexed citations

14.

Bruera, Gemma, Katia Cannita, Alessandra Tessitore, et al.. (2014). The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?. Critical Reviews in Oncology/Hematology. 93(3). 190–202. 22 indexed citations

15.

Bruera, Gemma, et al.. (2014). Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. International Journal of Oncology. 44(6). 1820–1830. 11 indexed citations

16.

Marampon, Francesco, Giovanni Luca Gravina, Luca Scarsella, et al.. (2013). Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. International Journal of Oncology. 44(1). 285–294. 37 indexed citations

17.

Bruera, Gemma, Katia Cannita, Aude Lamy, et al.. (2013). Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). BMC Medicine. 11(1). 59–59. 23 indexed citations

18.

Bruera, Gemma, et al.. (2013). Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. International Journal of Oncology. 44(1). 17–26. 10 indexed citations

19.

Bruera, Gemma & Enrico Ricevuto. (2011). Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Expert Opinion on Biological Therapy. 11(6). 821–824. 22 indexed citations

20.

Bruera, Gemma, Katia Cannita, Marianna Tudini, et al.. (2010). "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer. 10(1). 567–567. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact